TREOS BIO

Treos Bio Limited is a United Kingdom based biotechnology and healthcare company that stands out with its disruptive computational technology for cancer immunotherapy development. The company's slogan "Peptide Immunotherapy Digitally Matched to Patient Genetics" succinctly encapsulates its approach. Founded in 2013, Treos Bio has developed proprietary therapeutic peptides that can be produced through scalable processes without the need for tumor biopsy. This innovative approach addresses the challenges of patient and tumor heterogeneity, paving the way for clinically effective cancer-specific immune responses in patients predicted by the company's diagnostic tests to respond. The company recently received a significant boost in the form of a €14.00M Convertible Note investment on 31 March 2021. Notably, this investment came from Luminous Ventures and The Future Fund, demonstrating confidence in Treos Bio's technology and potential impact in the field of cancer immunotherapy. With its cutting-edge technology and strong investor backing, Treos Bio Limited is poised to make significant strides in revolutionizing cancer treatment through personalized peptide immunotherapy.